Physician profile
Mark A Ledoux
NPI 1356552509
$11,973.06
in general payments reported to CMS, 2019-2025
44 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 77% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $1,238 · 2021: $2,903 · 2022: $1,163 · 2023: $807 · 2024: $2,575 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,509 · Travel and Lodging: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,508.70 |
| Travel and Lodging | $402.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,698.41 | 2019-2025 | Eterna, Proclaim, Ionicrf |
| Painteq LLC | $1,606.52 | 2021 | |
| Collegium Pharmaceutical, INC. | $975.18 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $945.85 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, Intracept |
| Nalu Medical, INC. | $790.18 | 2020-2025 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $719.63 | 2019-2025 | Relistor |
| Saluda Medical Americas, INC. | $663.43 | 2024-2025 | Evoke |
| Medtronic, INC. | $396.89 | 2021-2025 | Intellis Adaptivestim |
| Abbvie INC. | $391.47 | 2022-2025 | |
| Horizon Therapeutics Plc | $359.65 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $344.76 | 2019-2025 | Ztlido |
| Nevro Corp. | $268.30 | 2019-2024 | Senza |
| Assertio Therapeutics, INC. | $247.38 | 2019-2020 | |
| Pacira Therapeutics, INC. | $232.11 | 2019-2021 | |
| Almatica Pharma LLC | $197.66 | 2021-2023 | Gralise |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $177.76 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $167.88 | 2019-2022 | |
| Daiichi Sankyo INC. | $162.57 | 2019 | |
| Allergan, INC. | $150.24 | 2020-2022 | |
| Ibsa Pharma INC. | $146.96 | 2020-2022 | |
| Amgen INC. | $131.01 | 2021-2022 | |
| Lundbeck LLC | $128.31 | 2025 | Vyepti |
| Curonix LLC | $120.52 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertex Pharmaceuticals Incorporated | $118.24 | 2025 | |
| Lilly USA, LLC | $107.54 | 2022-2023 | Emgality |
| Azurity Pharmaceuticals, INC. | $106.17 | 2023-2025 | Horizant, Horizant |
| Pfizer INC. | $87.21 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $79.54 | 2019-2021 | |
| Spr Therapeutics, INC | $68.39 | 2019-2025 | Sprint Pns System |
| Teva Pharmaceuticals USA, INC. | $66.13 | 2020-2021 | |
| Pacira Pharmaceuticals Incorporated | $45.83 | 2023-2025 | Zilretta, Iovera |
| Relievant Medsystems, INC. | $30.39 | 2022 | |
| Averitas Pharma INC. | $26.17 | 2023 | Qutenza |
| Tonix Medicines, INC. | $24.84 | 2025 | Tonmya |
| Biotronik Nro, INC. | $23.97 | 2025 | Prospera |
| Grt US Holding, INC. | $23.23 | 2022 | |
| Globus Medical, INC. | $23.22 | 2025 | Senza |
| Djo, LLC | $20.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.87 | 2019 | |
| Avanos Medical | $18.09 | 2021 | |
| Redhill Biopharma INC. | $17.53 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $16.66 | 2019 | |
| Zyla Life Sciences, INC. | $14.72 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ledoux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.